Brief: U.S. FDA Approves Tecvayli® In Combination With Darzalex Faspro® For Relapsed/Refractory Multiple Myeloma
06/03/2026 13:00
March 6 (Reuters) - Halozyme Therapeutics Inc HALO.O: U.S. FDA APPROVES TECVAYLI® IN COMBINATION WITH DARZALEX FASPRO® FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA Source text: ID:nPn3GlMDKa Further company coverage: HALO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets